Kirsi Bourget

676 total citations
18 papers, 525 citations indexed

About

Kirsi Bourget is a scholar working on Biochemistry, Molecular Biology and Cancer Research. According to data from OpenAlex, Kirsi Bourget has authored 18 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Biochemistry, 9 papers in Molecular Biology and 9 papers in Cancer Research. Recurrent topics in Kirsi Bourget's work include Eicosanoids and Hypertension Pharmacology (10 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Mitochondrial Function and Pathology (3 papers). Kirsi Bourget is often cited by papers focused on Eicosanoids and Hypertension Pharmacology (10 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Mitochondrial Function and Pathology (3 papers). Kirsi Bourget collaborates with scholars based in Australia, Malaysia and United Kingdom. Kirsi Bourget's co-authors include Michael T. Murray, Tristan Rawling, Todd M. Brusko, Mark A. Atkinson, John A. Todd, Jason D. Cooper, Christopher Lowe, David Clayton, Sarah Field and Linda S. Wicker and has published in prestigious journals such as Nature Genetics, The FASEB Journal and Journal of Medicinal Chemistry.

In The Last Decade

Kirsi Bourget

18 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kirsi Bourget Australia 9 200 185 163 91 90 18 525
Kaori Endo‐Umeda Japan 14 42 0.2× 231 1.2× 165 1.0× 195 2.1× 68 0.8× 24 591
Peter B. Ehmer Germany 8 173 0.9× 176 1.0× 69 0.4× 34 0.4× 24 0.3× 12 584
Sharada Katkuri United States 7 185 0.9× 592 3.2× 95 0.6× 102 1.1× 364 4.0× 7 1.0k
Wakashi Kitayama Japan 11 156 0.8× 187 1.0× 17 0.1× 68 0.7× 91 1.0× 18 547
Renee E. Vickman United States 11 28 0.1× 202 1.1× 74 0.5× 56 0.6× 121 1.3× 17 465
Dean J. Welsch United States 13 70 0.3× 313 1.7× 33 0.2× 60 0.7× 188 2.1× 22 686
Xin-Pu Miao China 7 52 0.3× 168 0.9× 93 0.6× 75 0.8× 50 0.6× 15 426
Yeo‐Jung Kwon South Korea 14 61 0.3× 394 2.1× 65 0.4× 22 0.2× 155 1.7× 28 596
A E Hornby United States 7 265 1.3× 304 1.6× 49 0.3× 65 0.7× 62 0.7× 7 540
Arwed Cleve Germany 10 103 0.5× 269 1.5× 51 0.3× 26 0.3× 128 1.4× 21 547

Countries citing papers authored by Kirsi Bourget

Since Specialization
Citations

This map shows the geographic impact of Kirsi Bourget's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirsi Bourget with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirsi Bourget more than expected).

Fields of papers citing papers by Kirsi Bourget

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirsi Bourget. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirsi Bourget. The network helps show where Kirsi Bourget may publish in the future.

Co-authorship network of co-authors of Kirsi Bourget

This figure shows the co-authorship network connecting the top 25 collaborators of Kirsi Bourget. A scholar is included among the top collaborators of Kirsi Bourget based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirsi Bourget. Kirsi Bourget is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
King, Amy S. H., et al.. (2025). Mitochondrial targeting and anticancer cell killing by arylurea-fatty acids containing in-chain sulfur atoms. Journal of Pharmaceutical Sciences. 114(9). 103933–103933. 1 indexed citations
2.
Bourget, Kirsi, et al.. (2024). The inositol-requiring enzyme 1 (IRE1) endoplasmic reticulum stress pathway promotes MDA-MB-231 cell survival and renewal in response to the aryl-ureido fatty acid CTU. The International Journal of Biochemistry & Cell Biology. 171. 106571–106571. 1 indexed citations
3.
Bourget, Kirsi, et al.. (2022). Inclusion of the in-chain sulfur in 3-thiaCTU increases the efficiency of mitochondrial targeting and cell killing by anticancer aryl-urea fatty acids. European Journal of Pharmacology. 939. 175470–175470. 3 indexed citations
4.
Bourget, Kirsi, et al.. (2022). Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells. Journal of Pharmaceutical Sciences. 111(8). 2180–2190. 1 indexed citations
5.
Bourget, Kirsi, et al.. (2022). The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells. Pharmacological Reports. 74(5). 998–1010. 4 indexed citations
6.
Chen, Yongjuan, Md. Khalilur Rahman, Kirsi Bourget, et al.. (2021). PTU, a novel ureido-fatty acid, inhibits MDA-MB-231 cell invasion and dissemination by modulating Wnt5a secretion and cytoskeletal signaling. Biochemical Pharmacology. 192. 114726–114726. 2 indexed citations
7.
8.
Rawling, Tristan, Hugo MacDermott-Opeskin, Ariane Roseblade, et al.. (2020). Aryl urea substituted fatty acids: a new class of protonophoric mitochondrial uncoupler that utilises a synthetic anion transporter. Chemical Science. 11(47). 12677–12685. 22 indexed citations
9.
Murray, Michael T., Ariane Roseblade, Yongjuan Chen, Kirsi Bourget, & Tristan Rawling. (2019). Carbon Chain Length Modulates MDA‐MB‐231 Breast Cancer Cell Killing Mechanisms by Mitochondrially Targeted Aryl−Urea Fatty Acids. ChemMedChem. 15(2). 247–255. 5 indexed citations
10.
Bourget, Kirsi, et al.. (2018). Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells. European Journal of Pharmaceutical Sciences. 129. 87–98. 8 indexed citations
11.
12.
Allison, Sarah E., Yongjuan Chen, Nenad Petrović, et al.. (2017). Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species. Biochemical Pharmacology. 143. 79–89. 32 indexed citations
13.
Rawling, Tristan, Kirsi Bourget, Sarah E. Allison, et al.. (2017). A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells. Journal of Medicinal Chemistry. 60(20). 8661–8666. 24 indexed citations
14.
Rawling, Tristan, Yongjuan Chen, Kirsi Bourget, et al.. (2017). A novel synthetic analogue of ω‐3 17,18‐epoxyeicosatetraenoic acid activates TNF receptor‐1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells. The FASEB Journal. 31(12). 5246–5257. 33 indexed citations
15.
Rawling, Tristan, et al.. (2014). Synthetic ω-3 Epoxyfatty Acids As Antiproliferative and Pro-apoptotic Agents in Human Breast Cancer Cells. Journal of Medicinal Chemistry. 57(17). 7459–7464. 31 indexed citations
16.
Cui, Pei, Tristan Rawling, Kirsi Bourget, et al.. (2013). Anti-proliferative actions of N′-desmethylsorafenib in human breast cancer cells. Biochemical Pharmacology. 86(3). 419–427. 5 indexed citations
17.
Cui, Pei, Tristan Rawling, Kirsi Bourget, et al.. (2012). Antiproliferative and Antimigratory Actions of Synthetic Long Chain n-3 Monounsaturated Fatty Acids in Breast Cancer Cells That Overexpress Cyclooxygenase-2. Journal of Medicinal Chemistry. 55(16). 7163–7172. 26 indexed citations
18.
Lowe, Christopher, Jason D. Cooper, Todd M. Brusko, et al.. (2007). Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nature Genetics. 39(9). 1074–1082. 307 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaori Endo‐Umeda Breakdown of academic impact, for papers by Peter B. Ehmer Breakdown of academic impact, for papers by Sharada Katkuri Breakdown of academic impact, for papers by Wakashi Kitayama Breakdown of academic impact, for papers by Renee E. Vickman Breakdown of academic impact, for papers by Dean J. Welsch Breakdown of academic impact, for papers by Xin-Pu Miao Breakdown of academic impact, for papers by Yeo‐Jung Kwon Breakdown of academic impact, for papers by A E Hornby Breakdown of academic impact, for papers by Arwed Cleve
Rankless by CCL
2026